Trials / Completed
CompletedNCT01171768
The Expression of Serum Angiogenesis Marker in Patients Presenting With Hemoptysis
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 52 (estimated)
- Sponsor
- Samsung Medical Center · Academic / Other
- Sex
- All
- Age
- 20 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
Vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) are major mediators of angiogenesis and are induced by tissue inflammation and hypoxia. While elevated serum VEGF levels have been reported in inflammatory lung diseases, especially with hemoptysis, there was no study to evaluate the Ang-2 levels in lung inflammatory diseases according to the presence of hemoptysis, inflammatory biomarker and hypoxia.
Conditions
Timeline
- Start date
- 2008-06-01
- Completion
- 2010-12-01
- First posted
- 2010-07-28
- Last updated
- 2011-07-21
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01171768. Inclusion in this directory is not an endorsement.